A private investment fund is formed for biotech and pharmaceutical companies

According to the financial news report, citing the public relations of the Innovation and Prosperity Fund, this agreement is for joint cooperation to expand the investment culture and finance entrepreneurship and technology for the development of human capital, promoting entrepreneurship and improving the emergence of successful businesses and in line with The implementation of Article 7 of the regulation on supporting the production of knowledge-based and job-creating in the field of health (approved by the Board of Ministers in July 1401) between Vahdat, Chairman of the Board of Directors of the Innovation and Prosperity Fund, Behzadpour, the General Manager of Central Insurance, and Qanei, the Secretary of the Bio-Technology Staff, Vice-Chancellor of Science, Technology And the knowledge-based economy of the presidency was signed today, Tuesday, March 16, 1401, at the Central Insurance Building of Iran.

Based on this agreement, a private investment fund (PE) will be established and formed, focusing on companies active in the fields of biotechnology, medicine and new treatments, with a priority on plasma-derived drug production plans.

The capital of this fund is 800 billion tomans, of which the share of the Central Insurance and Innovation Fund will be 200 billion tomans, and the share of the Zitest Technology Development Headquarters will be 150 billion tomans.